



Global Corporate Headquarters  
7 Argent Place, Ringwood  
Victoria 3134, Australia  
Tel: +61 (0) 3 9837 4200  
[www.trajanscimed.com](http://www.trajanscimed.com)

Trajan Group Holdings Limited  
ACN 152 617 706

**NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES**

## **ASX RELEASE**

### **Trajan announces the successful completion of the Share Purchase Plan**

**15 July 2022** - Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (**Trajan** or **the Company**) is pleased to announce the successful completion of the Company's Share Purchase Plan (**SPP**) announced on 17 June 2022 and closed at 5.00pm on Tuesday, 12 July 2022.

The SPP raised A\$4.7 million and follows the successful completion of a \$29.7 million institutional placement (**Placement**). Funds raised under the SPP will be used to support Trajan's growth objectives through further strategic acquisitions and organic growth opportunities.

Approximately 2.3 million new fully paid ordinary shares in the Company will be issued under the SPP (**SPP Shares**) at an issue price of \$2.00 per SPP Share, which is the same price that investors paid for shares under the Placement.

The SPP Shares are expected to be issued on Tuesday, 19 July 2022. Holding statements are expected to be dispatched on Wednesday, 20 July 2022, and any refunds (for example, as a result of invalid applications) will be processed in accordance with the terms of the SPP.

The SPP Shares will rank equally in all respects with Trajan's existing fully paid ordinary shares from the date of allotment.

#### **Further Information**

Further details on the Placement and SPP are set out in the Investor Presentation ("Trajan Capital Raising Presentation") lodged on the ASX on 17 June 2022. The Investor Presentation contains important information including key risks and foreign offer restrictions with respect to the Placement. For other questions, you should consult your broker, solicitor, accountant, tax adviser, financial adviser, or other professional adviser.

**END**

#### **Contact:**

##### **Investors**

Rebecca Wilson  
WE Communications  
[investorrelations@trajanscimed.com](mailto:investorrelations@trajanscimed.com)

##### **Media**

Amy Miller  
WE Communications  
[amymi@we-worldwide.com](mailto:amymi@we-worldwide.com)

#### **About Trajan**

Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to have a positive impact on human wellbeing through scientific measurement. These products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.



## **NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES**

Trajan is a global organisation of more than 650 people with seven manufacturing sites across the US, Australia, Europe, and Malaysia, and operations in Australia, the US, Asia, and Europe.

### **Important Notice**

#### **Not for distribution or release in the United States**

This announcement may not be distributed or released in the United States. This announcement does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. The New Shares to be offered and sold under the Offer and have not been, and will not be, registered under the U.S. Securities Act of 1933 (the "U.S. Securities Act") or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares may not be offered or sold, directly or indirectly, to any person in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and any other applicable U.S. state securities laws.

#### **Forward-looking statements**

The information in this announcement is subject to change without notice and Trajan is not obliged to update or correct it. This presentation contains statements that constitute "forward-looking statements". The forward-looking statements include statements regarding Trajan's intent, belief, or current expectations with respect to the timetable, conduct, and outcome of the Offer and the use of proceeds. This includes statements about the plans, objectives, and strategies of the management of Trajan, statements about the industry and markets in which Trajan operates, statements about the future performance of Trajan's business and its financial condition, indicative drivers, forecasted economic indicators, and the outcome of the Offer and the use of proceeds. Words such as "will", "may", "expect", "indicative", "intent", "seek", "would", "should", "could", "continue", "plan", "probability", "risk", "forecast", "likely", "estimate", "anticipate", "believe", "aim" or similar words are used to identify forward-looking statements.

You are strongly cautioned not to place undue reliance on forward-looking statements. Any such statements, opinions, and estimates in this presentation speak only as of the date hereof and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance, and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements contained in this announcement are not indications, guarantees, or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Trajan, its officers, employees, agents, and advisers, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct.

There can be no assurance that actual outcomes will not differ materially from these statements. Several important factors could cause actual results or performance to differ materially from the forward-looking statements, including (without limitation) the risks and uncertainties associated with the ongoing impacts of COVID-19, the Australian and global economic environment and capital market conditions, and other risk factors set out in this announcement. Investors should consider the forward-looking statements contained in this presentation in light of those risks and disclosures. The forward-looking statements are based on information available to Trajan as at the date of this presentation.

To the maximum extent permitted by law, responsibility for the accuracy or completeness of any forward-looking statements whether as a result of new information, future events or results, or otherwise is disclaimed. Trajan disclaims any responsibility to update or revise any forward-looking statement to reflect any change in Trajan's financial condition, status or affairs, or any change in the events, conditions, or circumstances on which a statement is based, except as required by law.